Clinical Trial Update: Safety Study of NNZ-2566 in Healthy Female Subjects [Phase 1]

View source ↗

Summary

The update reports a completed Phase 1 safety study of NNZ-2566 in healthy female volunteers, assessing safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• NNZ-2566

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Brain Injuries, Traumatic | Phase 1 | Status: COMPLETED